Ureaplasma urealyticum medical therapy
Ureaplasma urealyticum Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Ureaplasma urealyticum medical therapy On the Web |
American Roentgen Ray Society Images of Ureaplasma urealyticum medical therapy |
Risk calculators and risk factors for Ureaplasma urealyticum medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Fatimo Biobaku M.B.B.S [2]
Overview
Medical Therapy
Antibiotics are the mainstay of treatment for Ureaplasma infection. Antibiotic susceptibility testing should be done to avoid treatment failure because of the geographical differences in antibiotic resistance.
Recommended antibiotics[1][2][3]
- This is the drug of first choice.
- It is the most active tetracycline for Mycoplasma and Ureaplasma infection.
- It should be avoided in pregnant women and young children.
- Josamycin and clarithromycin are the most effective macrolides against Ureaplasma infection.
- Josamycin is often recommended for neonates and pregnant women, especially when mixed infection is present.
- Pristinamycin can be used as an alternative to Josamycin in pregnant women.
- Erythromycin has a low efficacy against Ureaplasma urealyticum.
- Fluoroquinolones: They have a low efficacy against urogenital Mycoplasma and Ureaplasma infection.
- Clindamycin: This has also been demonstrated to have a low efficacy against Ureaplasma species.
References
- ↑ De Francesco MA, Caracciolo S, Bonfanti C, Manca N (2013). "Incidence and antibiotic susceptibility of Mycoplasma hominis and Ureaplasma urealyticum isolated in Brescia, Italy, over 7 years". J Infect Chemother. 19 (4): 621–7. doi:10.1007/s10156-012-0527-z. PMID 23192735.
- ↑ Invalid
<ref>
tag; no text was provided for refs namedpmid26518581
- ↑ Lee MY, Kim MH, Lee WI, Kang SY, Jeon YL (2016). "Prevalence and Antibiotic Susceptibility of Mycoplasma hominis and Ureaplasma urealyticum in Pregnant Women". Yonsei Med J. 57 (5): 1271–5. doi:10.3349/ymj.2016.57.5.1271. PMC 4960396. PMID 27401661.